Page last updated: 2024-08-21

dronabinol and Metabolic Diseases

dronabinol has been researched along with Metabolic Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Hardy, DB; Lee, K1
Appendino, G; Calzado, MA; Eugenia Prados, M; Ferreiro-Vera, C; Garrido-Rodriguez, M; Morrugares, R; Muñoz, E; Nadal, X; Palomares, B; Ruiz-Pino, F; Sánchez-Garrido, MA; Tena-Sempere, M; Vazquez, MJ; Velasco, I1

Reviews

1 review(s) available for dronabinol and Metabolic Diseases

ArticleYear
Metabolic Consequences of Gestational Cannabinoid Exposure.
    International journal of molecular sciences, 2021, Sep-02, Volume: 22, Issue:17

    Topics: Animals; Cannabinoid Receptor Agonists; Dronabinol; Female; Fetal Growth Retardation; Humans; Lipid Metabolism; Liver; Metabolic Diseases; Placenta; Pregnancy; Prenatal Exposure Delayed Effects

2021

Other Studies

1 other study(ies) available for dronabinol and Metabolic Diseases

ArticleYear
Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity.
    Biochemical pharmacology, 2020, Volume: 171

    Topics: 3T3-L1 Cells; Adipogenesis; Adiposity; Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet, High-Fat; Dronabinol; Fatty Liver; HEK293 Cells; Humans; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone

2020